Summary of patient characteristics
| Characteristic . | Number of patients . |
|---|---|
| Total number of patients | 15 |
| Age (y), median (range) | 44 (17-70) |
| Sex | |
| Male | 9 |
| Female | 6 |
| Disease | |
| Acute myeloid leukemia | 12 |
| Non-Hodgkin lymphoma | 1 |
| Acute lymphoblastic leukemia | 2 |
| Disease status | |
| CR1 | 11 |
| CR≥2 | 4 |
| Conditioning regimen | |
| Myeloablative FLU/CY/TBI | 6 |
| Reduced Intensity FLU/CY/TBI | 9 |
| Number of UCB units infused | |
| 1 unit | 8 |
| 2 units | 7 |
| HLA matching | |
| 6 of 6 | 1 (7%) |
| 5 of 6 | 7 (47%) |
| 5 of 6/5 of 6 | 2 (13%) |
| 4 of 6/4 of 6 | 5 (33%) |
| TNC cell dose (× 107/kg recipient weight), median (range) | 3.02 (1.67-4.51) |
| CD34 cell dose (× 107/kg recipient weight), median (range) | 1.2 (0.7-6.5) |
| Characteristic . | Number of patients . |
|---|---|
| Total number of patients | 15 |
| Age (y), median (range) | 44 (17-70) |
| Sex | |
| Male | 9 |
| Female | 6 |
| Disease | |
| Acute myeloid leukemia | 12 |
| Non-Hodgkin lymphoma | 1 |
| Acute lymphoblastic leukemia | 2 |
| Disease status | |
| CR1 | 11 |
| CR≥2 | 4 |
| Conditioning regimen | |
| Myeloablative FLU/CY/TBI | 6 |
| Reduced Intensity FLU/CY/TBI | 9 |
| Number of UCB units infused | |
| 1 unit | 8 |
| 2 units | 7 |
| HLA matching | |
| 6 of 6 | 1 (7%) |
| 5 of 6 | 7 (47%) |
| 5 of 6/5 of 6 | 2 (13%) |
| 4 of 6/4 of 6 | 5 (33%) |
| TNC cell dose (× 107/kg recipient weight), median (range) | 3.02 (1.67-4.51) |
| CD34 cell dose (× 107/kg recipient weight), median (range) | 1.2 (0.7-6.5) |